Given that RAS blockers exhibit beneficial effects on metabolism in addition to their antihypertensive actions and exert a positive influence on affect (Pavel et al. 2008), we speculate that combination CB1‐AT1 receptor blockade might be additive or synergistic with potentially mitigated side effects of both treatments for management of metabolic syndrome considering the RAS‐dependent component associated with most forms of human hypertension. The gene discussed is AGTR1; the disease is hypertensive disorder.